Sustained β-catenin activation via GSK3 inhibition promotes direct fibroblast-to-cardiomyocyte reprogramming Authors: Xinghua Wang, Iqra Anwar, Richard E Pratt, Victor J Dzau, Conrad P Hodgkinson Published: 2026 ABSTRACT AbstractDuring iPSC differentiation, cardiomyocyte formation requires transient activation of canonical Wnt/β-catenin signaling followed by pathway inhibition. Inspired by the mechanisms governing iPSC differentiation into cardiomyocytes, this study sought to explore whether these pathways similarly affect direct fibroblast-to-cardiomyocyte reprogramming. In contrast to iPSC differentiation, direct reprogramming required early inhibition of glycogen synthase kinase-3 (GSK3), which leads to activation of β-catenin signaling, without a subsequent requirement for pathway suppression. Pharmacological GSK3 inhibition enhanced cardiomyocyte yield and improved functional maturation, as demonstrated by optical calcium mapping. Reporter assays confirmed increased β-catenin transcriptional activity, while non-canonical Wnt signaling was unaffected. Transcriptomic analysis revealed enhanced enrichment of muscle-associated gene ontology terms and modulation of immune and signaling pathways following GSK3 inhibition. Together, these findings suggest that although indirect and direct cardiac reprogramming share elements of Wnt pathway involvement, their temporal and mechanistic requirements differ substantially.Keywords: miR combo, fibroblasts, cardiac reprogramming, iPSCs, Wnt signaling pathway, heart regeneration Cardiovascular disease remains the leading cause of mortality worldwide (1). As such, there is an important need for innovative therapeutic strategies. Among the various strategies being investigated, cellular reprogramming has emerged as a promising approach for the regeneration of cardiac tissue following a heart attack. What cellular reprogramming seeks to do is to replace scar tissue with cardiac muscle by converting scar fibroblasts into cardiac muscle cells (cardiomyocytes). Cellular reprogramming is either indirect or direct. Indirect reprogramming involves the initial conversion of fibroblasts into induced pluripotent stem cells (iPSCs). These IPSCs, renowned for their pluripotency, are then differentiated into cardiomyocytes (2, 3). While iPSCs can generate large numbers of cardiomyocytes, the differentiation protocols are complex, and the resulting cells are generally immature. Direct cardiac reprogramming, which converts fibroblasts directly into cardiomyocytes without transitioning through a pluripotent state, generates cardiomyocytes that are mature. The issue is that direct reprogramming generates relatively low numbers of cardiomyocytes. Approaches to direct fibroblast-to-cardiomyocyte reprogramming involve transcription factors, pharmacological agents or miRNAs. Our laboratory has focused on the latter approach and developed a cocktail of four miRNAs (miR-1, miR-133, miR-208, and miR-499) called miR combo. Through the application of miR combo, we have shown that direct fibroblast-to-cardiomyocyte reprogramming requires epigenetic changes as well as the activation of RNA-sensing receptor signaling pathways (4, 5, 6, 7, 8). Despite the promise of these findings, it remains unclear whether other signaling pathways or mechanisms are involved. Importantly, once identified, these mechanisms could be exploited to improve efficacy. In this study, we hypothesized that strategies used to derive cardiomyocytes from iPSCs could be employed to enhance direct fibroblast-to-cardiomyocyte efficacy. Building upon previous research from both our laboratory and others, it has been demonstrated that derivation of cardiomyocytes from iPSCs involves the transient activation of canonical Wnt/β-catenin signaling followed by pathway inhibition (3, 9, 10). However, the role of this On-Off switch in direct fibroblast-to-cardiomyocyte reprogramming is poorly understood. Here, we demonstrate that akin to cardiomyocyte generation via iPSCs, the efficacy of direct fibroblast-to-cardiomyocyte reprogramming is improved by an early addition of GSK3 inhibitors, which are used as β-catenin activators. In contrast to iPSC differentiation to cardiomyocytes, turning off Wnt/β-catenin signaling has no benefit. Furthermore, GSK3 inhibitors improved both the yield and quality of cardiomyocytes derived from reprogramming fibroblasts. Results Activation of β-catenin increases miR combo reprogramming efficacy iPSCs undergo cardiomyocyte differentiation through a tightly regulated β-catenin On-Off switch. The initial activation of β-catenin signaling ("β-catenin on") facilitates cardiac mesoderm formation, while subsequent inhibition of β-catenin ("β-catenin off") is crucial for the transition to cardiac progenitor cells and the subsequent development of cardiomyocytes. This binary regulatory On-Off mechanism is essential for proper cardiac differentiation (11, 12, 13, 14). A common approach to generate cardiomyocytes from iPSCs involves increasing β-catenin via inhibition of Glycogen Synthase Kinase-3 (GSK-3) using CHIR99021 on day 0 of the protocol, followed by decreasing β-catenin via an inhibitor of Porcupine (PORCN) (Wnt-C59/IWR-1) on day 4 (10). Experiments were undertaken to determine the effect of this protocol on direct fibroblast-to-cardiomyocyte reprogramming. We chose several designs, whereby CHIR99021 and Wnt-C59 were either added alone or in combination at different timepoints during direct fibroblast-to-cardiomyocyte reprogramming (Fig. 1). Experimental timeline of protocols. Schematic representation of the experimental protocols. Protocols 1 to 5: Individual inhibitor treatments. Protocol 6: early administration of CHIR99021 and Wnt C59, applied 3 days before transfection. Protocol 7: standard iPSC differentiation to cardiomyocytes. Protocol 8: reversed the order of protocol 7. Following the approach of iPSC differentiation to cardiomyocytes, addition of CHIR99021 on day 0 and addition of Wnt-C59 on day 4 (Protocol 7), was found to substantially enhance the efficacy of direct fibroblast-to-cardiomyocyte reprogramming as evidenced by the significant upregulation of the expression of the cardiomyocyte-specific markers Actn2, Myh6, and Tnni3 (Fig. 2A). CHIR99021 enhances reprogramming efficacy.A, cardiac fibroblasts were transfected with miR combo or a non-targeting control miRNA. Where appropriate, CHIR99021 or Wnt-C59 were added as described in Figure 1. Fourteen days after transfection, expression of cardiomyocyte-specific genes Actn2, Myh6 and Tnni3 was determined by qPCR. Expression levels were normalized to the housekeeping gene Gapdh and are represented as fold changes relative to the non-targeting control miRNA group. N = 3 to 9 independent experiments. Significances were determined by ANOVA (Actn2 F(9,118) = 21.89, p < 0.0001; Myh6 F(9,117) = 16.64, p < 0.0001; Tnni3 F(9,118) = 20.16) and Tukey post hoc tests: ∗∗∗p< 0.001, ∗∗p< 0.01, ∗p< 0.05 vs. non-targeting control miRNA group (negmiR); ###p< 0.001 vs. miR combo. B, cardiac fibroblasts were transfected with miR combo or a non-targeting control miRNA. Vehicle or CHIR99021 was present from 0 to 2 days post-transfection. RNA was isolated 4 days after transfection from three independent experiments; equal amounts (10 μg) from each replicate were pooled for RNA-seq analysis. Genes exhibiting ≥5-fold changes relative to the non-targeting control were subjected to gene ontology (GO) analysis. The figure panel displays GO terms identified as representative nodes by Revigo, together with their false discovery rate (FDR)–adjusted p values and gene ratios. The left panel shows GO terms associated with upregulated genes, whereas the right panel shows those associated with downregulated genes. Notably, addition of CHIR99021 did not result in substantial further gene induction beyond that observed with the miR combo alone. To further investigate this finding, we expanded upon the standard protocol by introducing seven additional modifications to explore various conditions. These included (1): independent application of two inhibitors (Protocols 1–5, Fig. 1) (2); an advanced timing adjustment for CHIR99021 and Wnt-C59 administration by 3 days (Protocol 6, Fig. 1); and (3) a reversal in the order of inhibitor application (Protocol 8, Fig. 1). Among these seven protocols, only Protocol 2—where CHIR99021 was administered exclusively on the day of miR combo transfection in the absence of Wnt-C59—demonstrated the potential to enhance miR combo reprogramming efficiency compared to miR combo alone (Fig. 2A). Comparative analysis of Protocols two and seven revealed no significant differences in their effects on reprogramming efficiency, suggesting that the addition of Wnt-C59 on day 4 in Protocol seven does not confer additional benefit (Fig. 2A). Protocol two was used for the remainder of the study. Thus, our findings indicate that the key factor in enhancing miR combo efficacy is the exclusive addition of CHIR99021 on the day of transfection. The inability of Wnt-C59 to modulate fibroblast-to-cardiomyocyte reprogramming may reflect the mechanism of the pharmacological agent as a PORCN inhibitor, blocking Wnt ligand secretion rather than directly modulating β-catenin. To confirm the positive effect of CHIR99021 on direct fibroblast-to-cardiomyocyte reprogramming, various additional studies were conducted. In the first instance, RNA-seq was performed on RNA from cells reprogrammed in the presence of CHIR99021. When compared to control cells, the transcriptome of miR combo-transfected cells was enriched in cardiac muscle protein, cardiac ion channel, and signaling protein transcripts (Fig. 2B). The addition of CHIR99021 increased the significance of this enrichment (Fig. 2B). Transcript down-regulation in reprogramming cells was focused on proteins involved in receptor mediated signaling and immunity (Fig. 2B). The latter were a particular target of CHIR99021 (Fig. 2B). Next, assessments were made of cardiomyocyte structure and maturation. To that end, Actn2 protein was visualized via immunofluorescence (Fig. 3A). This allowed us to quantitate the number of cardiomyocyte-like cells as well as analyze their sarcomere structure. The addition of CHIR99021 led to a significant increase in the number of cardiomyocyte-like cells (Fig. 3B). Moreover, the addition of CHIR99021 decreased cardiomyocyte circularity index (Fig. 3C). A decreased circularity index is a hallmark of improved cardiomyocyte maturation (15). CHIR99021 enhances cardiomyocyte generation and maturation. Cardiac fibroblasts were transfected with miR combo or a non-targeting miRNA. CHIR99021 was added immediately after transfection. Cells were analyzed 14 days after transfection. Initially, the number of cardiomyocyte-like cells was quantified by immunostaining for the cardiomyocyte-specific protein Actn2. A, representative image of Actn2+ cell (scale bar shown). The inset picture shows a magnified view highlighting sarcomere structure. The two side-panels are individual channels. The Actn2 channel was used to calculate cardiomyocyte length (l) and width (w). B, quantification of cardiomyocyte number. Numbers are shown per well of a 12-well plate. Significances were determined by ANOVA (F(2,12) = 24.31, p < 0.0001) and Tukey post hoc tests: ∗∗∗p< 0.001, ∗p< 0.05 vs. non-targeting control miRNA group (negmiR); ##p< 0.01 vs. miR combo. N = 5 independent experiments. C, circularity index calculated by dividing l with w. Significances were determined by t test: #p< 0.05 vs. miR combo. N = 28 to 36 cells were measured from three independent experiments. Following the assessment of sarcomere structure, functional maturation was evaluated by optical calcium mapping. D, peak interval time. Data are presented as median with interquartile range. Statistical significance was determined using a one-sample t test (∗∗∗p< 0.001, ns – not not significant). N = 35 (miR combo) and N = 58 (miR combo + CHIR99021) cells from four independent experiments. E, representative calcium optical mapping traces from non-targeting control (negmiR; one cell), miR combo (3 cells), and miR combo + CHIR99021 (3 cells). Finally, calcium transients were evaluated. There was notable heterogeneity in the peak intervals of spontaneously beating cells in both groups. However, the addition of CHIR99021 to the reprogramming protocol significantly increased the peak interval time distribution (Fig. 3D). Moreover, CHIR99021 also resulted in more sustained calcium transients (Fig. 3E). Taken together, the data suggest improved calcium handling, a feature associated with cardiomyocyte maturation. CHIR99021 activates Wnt/β-catenin signaling Further studies were conducted on CHIR99021 specificity in cardiac fibroblasts. CHIR99021 activates β-catenin by virtue of being a GSK3 inhibitor. The activity of the β-catenin signaling pathway can be determined via the TOPFlash assay. In this assay, cells are transfected with plasmids containing a luciferase reporter coupled to either functional (TOP) or non-functional (FOP) TCF/LEF transcription factor binding sites. When Wnt signaling is activated, β-catenin accumulates in the cytoplasm and translocates to the nucleus. In the nucleus, β-catenin binds to TCF/LEF transcription factors. The ratio of TOP to FOP fluorescence determines the activity of β-catenin signaling pathway. As shown in Figure 4A, miR combo was unable to activate the β-catenin signaling pathway. In contrast, robust activation of the β-catenin signaling pathway was observed when CHIR99021 was added (Fig. 4A). CHIR99021 activates Wnt/β-catenin signaling.A, cardiac fibroblasts were transfected with either the TOP plasmid (functional TCF/LEF binding sites) or the FOP plasmid (non-functional TCF/LEF binding sites). After 2 days, cells were further transfected with either non-targeting control miR or miR combo. Vehicle or CHIR99021 were added to cells for 18 h. The TOP/FOP ratio is reported. N = 10 independent experiments. Data were analyzed using a one-sample Wilcoxon signed-rank test against a theoretical median of 1 (normalized control value), ∗∗∗p< 0.001 (comparison to the non-targeting miR control), ###p< 0.001 (comparison to miR combo). B, cardiac fibroblasts were transfected with a non-targeting miRNA or miR combo. Where indicated, CHIR99021 was added immediately after transfection for a total of 48 h. Four days after transfection, cell extracts were analyzed for phosphorylated JNK by immunoblotting. Representative immunoblots are shown. N = 3 independent experiments. Densitometry was performed to determine band intensity and values were normalized to Gapdh. Data were analyzed using a one-sample Wilcoxon signed-rank test against a theoretical median of 1 (normalized control value), ∗∗p< 0.001 (comparison to the non-targeting miR control). C, cardiac fibroblasts were transfected with either a non-targeting miRNA or miR combo. Immediately after transfection, TWS-119 was added to the cells for 48 h. Fourteen days post-transfection, qPCR was performed to measure cardiac-specific gene expression, normalized to Gapdh and results are shown as fold changes relative to the non-targeting control miRNA group. N = 4 independent experiments. Data were analyzed using a one-sample Wilcoxon signed-rank test against a theoretical median of 1 (normalized control value), ∗∗p< 0.01, ∗p< 0.05, ns – not significant. D, cardiac fibroblasts were transfected with either a non-targeting miRNA or miR combo. Immediately after transfection, Wnt3a was added to the cells. Two days later media was replaced. Fourteen days post-transfection, qPCR was performed to measure cardiac-specific gene expression, normalized to Gapdh. Expression data is represented as fold changes relative to the non-targeting control miRNA group N = 4 independent experiments. Data were analyzed using a one-sample Wilcoxon signed-rank test against a theoretical median of 1 (normalized control value), ∗∗p< 0.01, ∗p< 0.05, ns – not significant. Wnt signaling can also involve pathways that do not involve β-catenin. One of these non-β-catenin signaling pathways involves JNK phosphorylation. Alone, miR combo induced significant decreases in phospho-JNK levels (Fig. 4B). This decrease in phospho-JNK was not affected by CHIR99021 (Fig. 4B). Following these studies, we next determine if the effects we observed were due to GSK3 inhibition or were an artifact from the choice of pharmacological agent. To that end, we chose the GSK3 inhibitor TWS119. Consistent with the findings obtained with CHIR99021, TWS119 enhanced miR combo reprogramming efficacy when administered on the day of transfection (Fig. 4C). Finally, we wanted to determine if there was any difference between pharmacological agents (CHIR99021/TWS119) and natural ligands. One such natural ligand that has been implicated in cardiomyocyte differentiation is Wnt3a. Wnt3a can activate both β-catenin-dependent and β-catenin-independent signaling. While Wnt3a was found to increase miR combo efficacy, the effects were not significant (Fig. 4D). Impact of β-catenin signaling on modified miR combo We recently demonstrated that chemical modification of two of the constituent miRNAs of miR combo with a 5′ triphosphate group (modmiR combo) improved direct fibroblast-to-cardiomyocyte reprogramming efficacy (16). The mechanism of action was not determined. Consequently, we questioned whether CHIR99021 could be employed to ascertain the mechanism. ModmiR combo increased expression of the cardiomyocyte genes Actn2, Myh6, and Tnni3. However, the addition of CHIR99021 did not enhance modmiR combo reprogramming efficacy (Fig. 5A). Similarly, CHIR99021 had no impact on the ability of modmiR combo to generate cardiomyocyte-like cells (Fig. 5B). CHIR99021 does not potentiate modmiR combo directed cardiac reprogramming.A, cardiac fibroblasts were transfected with modmiR combo or the respective modified non-targeting control miRNA. Cells were incubated with CHIR99021 for 48 h 3 days prior to transfection or immediately after transfection. Fourteen days after transfection, the expression level of cardiac-specific genes was determined by qPCR. Expression levels were normalized to the housekeeping gene Gapdh and are represented as fold changes relative to the non-targeting control miRNA group. N = 3 to 4 independent experiments. Data were analyzed using a one-sample Wilcoxon signed-rank test against a theoretical median of 1 (normalized control value), ∗p< 0.05, ns – not significant. B, cardiac fibroblasts were transfected with a non-targeting miRNA or modmiR-Combo. CHIR99021 was added immediately after transfection. Fourteen days after transfection, the number of cardiomyocyte-like cells was quantified by immunostaining for the cardiomyocyte-specific protein Actn2. Both the number of cardiomyocyte-like cells as well as their circularity index were calculated. Representative images are shown far right. Scale bar 50 microns. N = 4 to 19 independent experiments. Left panel, ANOVA (F(2,9) = 40.75, p < 0.0001) and Tukey-post hoc tests were used to determine significance, ns – not significant. Right panel, no cardiomyocytes were present in control group and a student t test was used to determine the significance between the indicated columns, ns – not significant. C, cardiac fibroblasts were transfected with modmiR combo or the respective modified non-targeting control miRNA. Where appropriate, cells were incubated with CHIR99021 for 48 h immediately after transfection and Wnt-C59 for 48 h starting from 4 days after transfection. Fourteen days after transfection, the expression level of cardiac-specific genes was determined by qPCR. Expression levels were normalized to the housekeeping gene Gapdh and are represented as fold changes relative to the non-targeting control miRNA group. N = 4 to 6 independent experiments. Data were analyzed using a one-sample Wilcoxon signed-rank test against a theoretical median of 1 (normalized control value), ∗p< 0.05, ns – not significant. D, the experiment in panel C was repeated, except the timing of CHIR99021 and Wnt-C59 treatment was reversed. N = 3 independent experiments. Data were analyzed using a one-sample Wilcoxon signed-rank test against a theoretical median of 1 (normalized control value), ∗p< 0.05, ns – not significant. Interestingly, of the eight protocols we employed, only Protocol 7 - where CHIR99021 was administered on day 0, followed by Wnt-C59 on day 4 - led to a significant upregulation of cardiomyocyte-specific genes (Fig. 5C). The effect of Wnt-C59 was lost if it was added at the beginning of the protocol (Fig. 5D). Comparative analysis of the data suggested that Wnt-C59 treatment on day 4 was the primary determinant, whereas CHIR99021 administration alone had no significant impact on modmiR combo ability to induce reprogramming. The effects of β-Catenin are mediated by IFNβ we wanted to determine in more detail how β-catenin was regulating cardiomyocyte-specific gene expression. Given the differential responses to CHIR99021 between miR combo and modmiR combo, we hypothesized that modmiR combo may intrinsically activate β-catenin signaling, thereby diminishing the effect of additional CHIR99021 treatment. To test this hypothesis, we assessed β-catenin expression and phosphorylation via confocal imaging and immunoblot analysis. Confocal imaging revealed significantly elevated β-catenin levels in both the cytoplasm and nucleus of the modmiR combo group relative to miR combo (Fig. 6A). Immunoblot analysis corroborated these findings, demonstrating increased total β-catenin levels in all treated groups compared to control cells. Notably, phosphorylated β-catenin levels were significantly reduced in both the CHIR99021 and modmiR combo groups compared to miR combo alone (Fig. 6B). IFNβ promotes direct fibroblast reprogramming via β-catenin.A, cardiac fibroblasts were transfected with miR combo, modmiR combo, or their respective non-targeting controls. Four days after transfection, β-catenin expression level was determined by immunostaining, and fluorescence intensity was quantified. N = 10 to 12 independent experiments. Representative images are shown (β-catenin: red, DAPI: blue) with a 20 micron scale bar. Data were analyzed using a two-way ANOVA. There was no significant interaction between factors (F(4,90) = 0.113, p= 0.978). The row factor was significant (F(2,90) = 6.95, p= 0.0016), and the column factor was highly significant (F(2,90) = 124.7, p< 0.0001). Post hoc comparisons were performed using Tukey’s test where appropriate. B, cardiac fibroblasts were transfected with a non-targeting miRNA, miR combo or modmiR combo. Where indicated, CHIR99021 was added immediately after transfection for a total of 48 h. Four days after transfection, cell extracts were analyzed for total and phosphorylated β-catenin as well as for IFNβ pathway proteins IRF3 and NLRP3.by immunoblotting. Representative immunoblots are shown. N = 4 independent experiments. Densitometry was performed to determine band intensity and values were normalized to Gapdh. Data were analyzed using a one-sample Wilcoxon signed-rank test against a theoretical median of 1 (normalized control value). Comparisons were made to control cells (∗∗∗p < 0.001, ns – not significant) and miR combo (###p < 0.001). C, cardiac fibroblasts were transfected with modmiR combo or a non-targeting miRNA control. Five hours after transfection an isotype control or IFNβ blocking antibody (Ab) was added to the media. One day after transfection media was replaced with fresh media. Four days post-transfection, immunoblot analysis was performed for total and phosphorylated β-catenin. Representative blots are shown. N = 3 independent experiments. Densitometry analysis was performed, with band intensities normalized to Gadph. Data were analyzed using a one-sample Wilcoxon signed-rank test against a theoretical median of 1 (normalized control value). Comparisons were made to control cells (∗∗∗p < 0.001, ∗p < 0.05, ns – not significant) and miR combo (##p < 0.01). We recently demonstrated that improved direct fibroblast-to-cardiomyocyte reprogramming efficacy observed with modmiR combo required IFNβ. Considering the similarities between CHIR99021 and modmiR combo, we hypothesized that IFNβ was playing a role in β-catenin phosphorylation. Indeed, immunoblot analysis 4 days post-transfection revealed a marked downregulation of IFNβ pathway proteins IRF3 and NLRP3 in both the CHIR99021 and modmiR combo groups (Fig. 6B). Importantly, blocking IFNβ activity with a specific antibody led to a significant increase in β-catenin phosphorylation levels (Fig. 6C). These findings suggest that IFNβ activates β-catenin by suppressing β-catenin phosphorylation. Discussion In this study, we demonstrate that fibroblast-to-cardiomyocyte reprogramming efficiency is enhanced by inclusion of the GSK3 inhibitor CHIR99021. Addition of CHIR99021 to the reprogramming protocol increased the number of induced cardiomyocytes by ∼2.5 fold and promoted features consistent with improved functional maturation. Mechanistically, the comparable effects observed with CHIR99021 and TWS119 strongly implicate GSK3 inhibition as a central player. Although CHIR99021 is widely used as an activator of β-catenin signaling, its primary action is inhibition of GSK3. Consistent with β-catenin pathway activation, we observed a significant increase in transcriptional activity in the TOPFlash reporter assay. Furthermore, CHIR99021 did not alter phospho-JNK levels, suggesting that non-canonical Wnt/β-catenin–independent signaling was not measurably engaged under these conditions. Interestingly, CHIR99021 also reduced expression of components of the IFNβ signaling pathway. This finding suggests that the effects of CHIR99021 may not be mediated exclusively through β-catenin. In addition, Wnt3a, representing receptor-mediated activation of the β-catenin pathway, did not reproduce the magnitude of the CHIR99021 response. This could be due to the ability of Wnt3a to activate pathways independently of β-catenin or that effective reprogramming in our system may require a degree of β-catenin stabilization that exceeds physiological ligand-driven activation. The β-catenin signaling pathway plays a pivotal role in the differentiation of iPSCs into cardiomyocytes as well as in cardiac development (9, 12, 17). The role played by β-catenin is biphasic. Initial activation of the β-catenin pathway promotes cardiogenesis by inducing ventrolateral mesoderm and precardiac mesoderm formation, whereas progenitor formation and differentiation into cardiomyocytes requires β-catenin inhibition (18, 19, 20). This dual-phase regulation of β-catenin has become a cornerstone of iPSC-derived cardiomyocyte differentiation protocols (21, 22, 23). The role of dual-phase regulation of β-catenin with respect to direct fibroblast-to-cardiomyocyte reprogramming is less clear. Wang et al. reported that down-regulation of the protein Beclin1 improved a transcription-based protocol for direct fibroblast-to-cardiomyocyte reprogramming via down-regulation of β-catenin (23). However, the authors noted that Beclin1 also reduced PI3K activity. Mohamed et al. and Singh et al. reported that transcription-based direct fibroblast-to-cardiomyocyte reprogramming was enhanced by the addition of ICG-001 and XAV939 respectively (24, 25). Like CHIR99021, their effects on β-catenin are indirect. ICG-001 specifically binds to cyclic AMP response element-binding protein and XAV939 targets tankyrase. These findings, as well as ours, highlight the need for further exploration of the temporal and mechanistic intricacies of β-catenin signaling in direct fibroblast-to-cardiomyocyte reprogramming with more specific tools than that are currently available. Studies with CHIR99021 have also proven valuable for our recently reported modmiR combo. ModmiR combo, whereby two of the constituent miRs were modified with a 5′ triphosphate group, improves fibroblast-to-cardiomyocyte reprogramming. While we identified IFNβ as a key mediator, the downstream mechanism proved intractable. In this manuscript, we showe that modmiR combo intrinsically mimicked the effect of CHIR99021, rendering additional CHIR99021 treatment redundant and ineffective. This observation implies that the superior reprogramming efficiency of modmiR combo over traditional miR combo is likely due to GSK3 inhibition and potentially due to β-catenin. The data implies that IFNβ may function a key regulatory factor linking β-catenin signaling and cardiac cell fate determination, further reinforcing the intricate relationship between immune signaling and cardiac reprogramming mechanisms. These insights contribute to the broader understanding of cardiac differentiation and offer potentially valuable perspectives for developing more effective cardiac regeneration strategies. Experimental procedures Cell isolation and culture Cardiac fibroblasts were isolated from 1-day-old neonatal C57BL/6 mice following the method described by Jayawardena et al. (26). Once isolated, these fibroblasts were grown in growth medium consisting of DMEM (ATCC, catalog number 30–2002) supplemented with 15% v/v fetal bovine serum (Genessee) and 1% v/v penicillin/streptomycin (GIBCO, catalog number 15140-122). The cells were routinely passaged when they reached 70%–80% confluence, using a 0.05% w/v trypsin solution (GIBCO, catalog number 25300-054). All experimental procedures involving animals were conducted with the approval of Duke University's Division of Laboratory Animals (DLAR) and the Duke Institutional Animal Care and Use Committee (IACUC), under the protocol number A035-22-02. Transfection of cardiac fibroblasts with miR combo Fibroblasts initially cultured as passage zero were used for experiments at passage two. These cells were seeded at a density of 5000 cells per square centimeter in growth medium in a 12-well plate. Twenty-four hours after seeding, transfection was performed using Dharmafect-I (Horizon Discovery, catalog number T-2001-03). Each well of a 12-well plate received 5 nmol of miRNAs. Transfections were carried out according to the guidelines provided by the manufacturer. After 24 h, the transfection complexes were removed, and the fibroblasts continued to be cultured in growth medium for the remainder of the study with media changes every 48 h. Small molecules CHIR99021 (Sigma Aldrich, 5 nM, catalog number SML1046-5 MG), Wnt3a (Novus Biologicals, catalog number 5036-WN-010), Wnt-C59 (Selleck Chemicals, 2 μM, catalog number S7037), TWS-119 (Selleck Chemicals, 2 μM, catalog number S1590) and AR-A014418 (Selleck Chemicals, 1 nM, catalog number S7435) were sourced from commercial suppliers. The IFNβ-neutralizing antibody was obtained from BioLegend (catalog number 508108). qPCR Total RNA was isolated using the Quick-RNA MiniPrep Kit (Zymo Research, catalog number R1055) according to the manufacturer’s protocol. RNA was then converted into cDNA using the high-capacity cDNA reverse transcription kit from Applied Biosystems (catalog number 4368814) in a reaction volume of 40 μl. For qPCR, 4 μl of the synthesized cDNA was used along with FAM-tagged gene-specific primers and TaqMan Gene Expression Master Mix, both from Applied Biosystems, Waltham, MA, USA. The qPCR primers for Gapdh (Mm99999915_m1, catalog number 4331182), Actn2 (Mm00473657_m1, catalog number 4331182), Myh6 (Mm00440359_m1, catalog number 4331182) and Tnni3 (Mm00437164_m1, catalog number 4331182), were obtained from Thermo Fisher. The expression levels were quantified by normalizing to the housekeeping gene Gapdh. RNA-seq RNA was sequenced on an Illumina NovaSeq X Plus platform. Sequencing data was initially filtered for quality (Q > 30) and sequencing adaptors removed (TrimGalore!). The resulting sequences were aligned to the mouse genome (mm10) via HISAT2. Counts per gene were determined by FeatureCounts and normalized by dividing the gene count number by the total sequencing count to enable comparisons between samples. Genes whose expression changed by 5-fold or greater underwent gene ontological analysis (Panther). To reduce redundancy, and to identify key features, the large number of significant gene ontological terms (>400) underwent semantic analysis by Revigo. Nodal gene ontological terms identified by Revigo were subsequently plotted by both gene ratio (the number of genes identified in the gene ontological term divided by the total number of significant genes) and the FDR (false discover rate) adjusted p-value. Immunofluorescence and confocal microscopy Cells were first fixed using 2% (v/v) paraformaldehyde (EMS) as previously described (2). Subsequently, cells were blocked using an antibody buffer composed of 5% w/v BSA and 0.1% v/v Tween-20 in PBS for 1 hour at room temperature. Overnight incubation at 4 °C followed, using an Actn2 antibody (Sigma, catalog number A7811, 1:100) or a β-catenin antibody (Cell Signaling Technology, catalog number 9562S, 1:100) diluted in the same antibody buffer. The next day, cells were washed thrice with PBS and then incubated with Alexa Fluor-conjugated secondary antibodies (Invitrogen, goat anti-mouse 594 nm, catalog number A-21203) at a dilution of 1:500 in antibody buffer for 1 hour at room temperature. Nuclear staining was conducted with 4′, 6-diamidino-2-phenylindole (DAPI) at a concentration of 1 μg/ml in the antibody buffer for 30 min at room temperature. After a final wash in PBS to clear any unbound staining complexes, the cells were examined under a Zeiss Axiovert 200 inverted microscope. Images were randomly captured in six replicates per well by a researcher blinded to the experimental conditions. Immunoblotting As described in previous work (8), cells were washed once with PBS, and proteins were extracted using 150 μl of lysis buffer [62.5 mM Tris pH 8, 1% (v/v) SDS, 1% (v/v) mammalian protease inhibitor cocktail (Sigma, catalog number P8340-5 Ml), and 10% (v/v) phosphatase inhibitor cocktail (Roche, catalog number 4906837001, one tablet dissolved in 1 ml of water)] per well in a 6-well plate on ice. The proteins were then separated by SDS-PAGE (Invitrogen, catalog number NP0335BOX) and transferred onto nitrocellulose membranes (Bio-Rad, catalog number 1620115). Membranes were incubated overnight at 4°C with a primary antibody diluted in antibody buffer (50 mM Tris-HCl, 150 mM NaCl, 5%w/v BSA, 0.1%v/v Tween-20, pH 7.4). Afterward, the membranes were washed three times with Tris-buffered saline (TBS)-Tween (50 mM Tris-HCl, 150 mM NaCl, 0.1%v/v Tween-20, pH 7.4) at room temperature and incubated for 1.5 h with HRP-conjugated secondary in the antibody buffer. Following three additional washes with TBS-Tween, protein bands were detected using chemiluminescence (Cytiva, catalog number RPN2235). Band intensities were analyzed with either Image J or Syngene software. Primary antibodies used were β-catenin (Cell Signaling, catalog number 9562S), Phospho-β-Catenin (Cell Signaling, catalog number 9561S, targets the GSK3β phosphorylation sites S33, S37, and T41), IRF-3 (Cell Signaling, catalog number 4302S), NLRP3 (Cell Signaling, catalog number 15101), and Gapdh (Cell Signaling, catalog number 5174), all diluted 1:1000. Secondary HRP-conjugated antibodies (Cell Signaling, catalog number 7074S) were also used at a 1:1000 dilution. All antibodies were validated by the manufacturer. Calcium transients Cells were washed once with Ca2+-free Tyrode’s solution and loaded with 10 μM CAL-520 (AAT Bioquest, catalog number 21130,) for 1 h. Following dye loading, cells were incubated for 30 min in a 1:1 mixture of growth medium and Tyrode’s solution containing 1.8 mM CaCl2 prior to imaging. Line-scan recordings were obtained using a Zeiss LSM 510 Meta confocal microscope (Carl Zeiss AG) at a spatial resolution of 0.1 μm per pixel. Ca2+ transients were analyzed using Fiji (ImageJ). Statistics Experiments with two groups were analyzed using Independent T-tests. For experiments involving more than two groups, we employed ANOVA followed by Tukey’s correction to evaluate the significance of differences between groups. Data availability All data are contained within the article. Conflict of interest The authors declare that they do not have any conflicts of interest with the content of this article. Acknowledgment We thank the Edna and Fred Mandel Jr Foundation for their support. Author contributions C. P. H., V. D., R. P., X. W., and I. A. writing–review & editing; C. P. H. and X. W. writing–original draft; C. P. H. and V. D. supervision; R. P., C. P. H., and V. D. project administration; C. P. H. and R. P. methodology; C. P. H., I. A., and X. W. investigation; C. P. H. funding acquisition; C. P. H., V. D., R. P., and X. W. formal analysis; C. P. H. and X. W. data curation; C. P. H. and X. W. conceptualization. Funding and additional information The NHLBI grant R01-HL178582 provides support for X. W., I. A., REP and C. P. H. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Reviewed by members of the JBC Editorial Board. Edited by Roger Colbran References Associated Data Data Availability Statement All data are contained within the article.